Eli Lilly drug LY3499446, a new compound under development as KRAS G12C inhibitors (NCT #04165031), will be evaluated as a single agent or in combination with other agents such as abemaciclib, cetuximab, and erlotinib in advanced solid tumors including NSCLC (81). Here, KRAS is linked to non-small cell lung carcinoma.